Disease Domain | Count |
---|---|
Neoplasms | 4 |
Top 5 Drug Type | Count |
---|---|
Therapeutic radiopharmaceuticals | 4 |
Peptide Conjugate Radionuclide | 1 |
Top 5 Target | Count |
---|---|
PSMA(Prostate-specific membrane antigen) | 1 |
Target |
Mechanism PSMA inhibitors [+1] |
Active Org. ARTBIO, Inc.Startup |
Originator Org. ARTBIO, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhaseEarly Phase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. ARTBIO, Inc.Startup |
Originator Org. ARTBIO, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. ARTBIO, Inc.Startup |
Originator Org. ARTBIO, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date06 Mar 2023 |
Sponsor / Collaborator ARTBIO, Inc.Startup |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
212Pb-NG001 ( PSMA ) | Metastatic castration-resistant prostate cancer More | Phase 1 Clinical |
ABC(ARTBIO) | Solid tumor More | Preclinical |
ABB(ARTBIO) | Solid tumor More | Preclinical |
ABA(ARTBIO) | Solid tumor More | Preclinical |